Core Insights - Revvity, Inc. (RVTY) is expected to report its third-quarter 2025 results on October 27, with a history of earnings surprises, averaging 6.60% over the last four quarters [1][3] Q3 Performance Expectations - The company is anticipated to have a mixed but resilient performance in the second half of 2025, with the Life Sciences segment showing sustained momentum while facing challenges in Diagnostics, particularly in China [2] - The Zacks Consensus Estimate for revenues is $700 million, reflecting a 2.3% increase year-over-year, while earnings are expected to decline by 10.9% to $1.14 per share [3] - RVTY projects organic revenue growth to be flat to a 2% increase, translating to total revenues between $690 million and $705 million, with adjusted operating margins around 26% [4] Life Sciences Segment - The Life Sciences segment is expected to maintain its growth trajectory, particularly driven by the Signals Software business, which grew approximately 30% organically in the previous quarter [5] - Revenue estimates for the Life Sciences segment are projected at $308.7 million, a 2.6% increase year-over-year [6] Diagnostics Segment - The Diagnostics segment faces a challenging outlook, with strong performance outside of China but significant declines in multiplex testing volumes within China due to policy changes [7] - Revenue estimates for the Diagnostics segment are pegged at $392.5 million, reflecting a 2.5% year-over-year increase [8] Additional Factors - Recent product launches, such as the IDS i20 analytical platform and Mimix reference standards, are expected to contribute positively to revenues in the Diagnostics segment [10][11] - The introduction of pHSense reagents is anticipated to support growth in oncology and precision medicine, potentially enhancing revenue streams [12]